Skip to search formSkip to main contentSkip to account menu

gefitinib 250 MG Oral Tablet [Iressa]

Known as: GEFITINIB 250 mg ORAL TABLET, COATED [IRESSA], Iressa 250 MG Oral Tablet 
National Institutes of Health

Related topics

Related topics

15 relations
Croscarmellose SodiumIressaLactose MonohydrateMagnesium stearate

Broader (1)

gefitinib Oral Tablet [Iressa]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract 1875A: Preclinical proof of concept for the first Nanocyclix TKI-PET radiotracer targeting activated EGFR positive lung tumors
Background: IMAkinib® program is an innovative approach, based on Nanocyclix® chemistry technology, which aims to develop new… 
2014
2014
Abstract 4875: In vivo and in vitro generation and characterisation of EGFR-TKI resistance in patient-derived xenograft (PDX) and cell line-derived xenograft (CDX) models of NSCLC with activating…
Background: Non-small cell lung cancer (NSCLC) patients that have activating mutations in the epidermal growth factor receptor… 
2013
2013
Abstract 5651:In vivogeneration of EGFR-TKI resistance in a patient-derived xenograft (PDX) with an activating EGFR mutation (L858R), and molecular characterisation of resistance mechanisms..
BACKGROUND: Non-small cell lung cancer (NSCLC) patients that have activating mutations in the EGFR gene are treated with… 
2008
2008
Amfiregulin i prostatakreft : En mulig markør for behandlingsresistens mot Iressa (gefitinib)?
2006
2006
Einfluss des Tyrosinkinaseinhibitors ZD1839 (Iressa®) als Monotherapie und in Kombination mit hyperfraktionierter Bestrahlung auf die Proliferation von high-grade Gliomen in vitro unter Ber…
Review
2005
Review
2005
Oncogenes as Novel Targets for Cancer Therapy (Part I)
In the past 10 years, progress made in cancer biology, genetics, and biotechnology has led to a major transition in cancer drug… 
Review
2005
Review
2005
Spotlight on Gefitinib in Non-Small-Cell Lung Cancer
Gefitinib (Iressa™), the first commercially available epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitor, is… 
2004
2004
De l'importance des mutations dans les récepteurs aux facteurs de croissance sur la sensibilité aux inhibiteurs : après EGFR (HER1) et Iressa®, voici HER2 et Herceptin®
2004
2004
Wachstumsfördernde Signalübertragungswege
ZusammenfassungDie Zellproliferation und das Überleben maligner Zellen werden durch intrazelluläre Signalübertragungsmoleküle… 
2003
2003
Implications thérapeutiques du récepteur du facteur de croissance épidermique dans le cancer bronchique
Le cancer bronchopulmonaire est un cancer tres frequent, associe a une forte mortalite. Les progres therapeutiques ont ete tres… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)